Insights
Search Results
Client Highlights
6.27.25
Firm Advises ArrePath on IP Matters Related to Financing Round
On June 23, 2025, ArrePath, a company applying its proprietary artificial intelligence and machine learning platform together with deep R&D technical expertise to address the challenge of best-in-class antibacterial drug discovery, announced that it has raised a new round of financing to advance its pipeline and continue to expand the scope and capabilities of its discovery platform. The Boehringer Ingelheim Venture Fund led the financing, which also included existing investors Insight Partners, Innospark, and Nor’easter Ventures, and new investor AB Magnitude. Wilson Sonsini Goodrich & Rosati advised ArrePath on IP matters related to the transaction.
Client Highlights
8.03.23
Wilson Sonsini Advises Apton on Patent Matters in Acquisition
On August 2, 2023, Pacific Biosciences of California (PacBio), a leading provider of high-quality, long-read sequencing platforms, announced that it has signed a definitive merger agreement to acquire Apton Biosystems, Inc. (Apton), a Bay-Area-based company developing a high throughput short-read sequencer using state-of-the-art optics and image processing, paired with novel clustering and chemistry, that is designed to enable the sequencing of billions of clusters of DNA on one flow cell. Wilson Sonsini Goodrich & Rosati is representing PacBio in the transaction. Wilson Sonsini advised Apton Biosciences on patent matters related to the transaction.
Client Highlights
9.13.22
Wilson Sonsini Advises Good Therapeutics on IP Matters Related to Acquisition by Roche
On September 7, 2022, Good Therapeutics, a privately held company founded to create a new class of conditionally active therapeutics, announced it has entered into a definitive merger agreement to be acquired by Roche. With this acquisition, Roche will gain rights to Good Therapeutics’ innovative, conditionally active, PD-1-regulated IL-2 program and an exclusive right to the platform technology for the development of PD-1-regulated IL-2 receptor agonist therapeutics. Wilson Sonsini Goodrich & Rosati advised Good Therapeutics on IP matters related to the transaction.